Skip to main content

Phase 1/2 clinical testing of clade C-based HIV-1 candidate vaccines in China

Objective

The number of people living with HIV/AIDS in China is estimated to be >600,000, and projected to rise exponentially. Based on an in depth characterization of the epidemiological situation, three candidate vaccines - an innovative DNA vaccine and two different types of recombinant vaccine viruses - encoding a synthetic , Chinese clad C (CN54) derived Envy and GagPolNef polygene will be tested in a phase 1/2 clinical trial in China. 90 selected HIV negative volunteers will be vaccinated according to different prime/boost regimens and assessed for the safety and immunogenicity of the candidate vaccines. Emphasis will be put on the characterization of (cross-clade) cellular and humoral immune responses towards different regional virus strains. The proposed project also aims to establish the necessary infrastructure for future field trials.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITAET REGENSBURG
Address
11,Frans-joseph-strauss-allee 11
93053 Regensburg
Germany

Participants (3)

NATIONAL CENTER FOR AIDS PREVENTION AND CONTROL
China
Address
Nanwei Road 27, Xuanwu District
100050 Beijing
PEKING UNION MEDICAL COLLEGE HOSPITAL
China
Address
Shuaifuyuan 1, Wangfujing
100730 Beijing
UNIVERSITE PIERRE ET MARIE CURIE - PARIS VI
France
Address
Boulevard De L'hopital, 47-83
75651 Paris